OnQ Prostate Vendor Validation: From Research to Clinical Adoption

Prostate MRI has become an essential tool in prostate cancer detection and treatment planning. One of the greatest challenges in clinical imaging today is variability-differences in MRI platforms, field strengths, and acquisition approaches can influence image quality and diagnostic confidence. OnQ Prostate was initially implemented on GE and Siemens 3T systems in a research setting. With Cortechs.ai’s commitment to delivering clinically ready AI solution we have expanded to include Fuji, Canon, United, and Philips, on both 1.5T and 3T systems.

At Cortechs.ai, we believe advanced AI solutions must deliver consistent, reliable performance regardless of where or how they are deployed. That’s why vendor validation is a foundational element of OnQ Prostate.

Why Vendor Validation Matters

Vendor validation helps ensure that OnQ Prostate delivers dependable performance by confirming that:

  • Quantitative outputs remain reliable across supported MRI vendor platforms
  • Qualitative outputs are intuitive and clinically meaningful
  • Reports are clear, consistent, and suitable for routine clinical use and reimbursement

For AI-powered prostate imaging, vendor validation is not optional, it is essential for clinical trust and scalability.

Designed for Real-World, Multi‑Vendor Imaging

OnQ Prostate is built with real-world clinical environments in mind. Vendor validation testing confirms that when supported MRI input such as T2-weighted imaging and RSI diffusion-weighted imaging are provided, the software consistently generates high-quality, clinically usable outputs across vendor platforms.

Throughout validation testing, OnQ Prostate demonstrated reliable performance in generating:

  • Restricted Signal Maps
  • Color Fusion Maps
  • ADC and Trace-Weighted Images
  • Quantitative Prostate Reports

Clinical reviewers consistently found these outputs to be intuitive, legible, and easy to interpret, supporting efficient and confident prostate MRI review across imaging environments.

Supporting Clinical Confidence at Scale

Vendor validation helps ensure that OnQ Prostate delivers dependable qualitative and quantitative insight-even in diverse, multi‑vendor imaging environments. By reducing technical uncertainty, radiologists can focus on what matters most: interpretation, diagnosis, and patient care.

With OnQ Prostate, imaging teams benefit from:

  • Confidence in prostate MRI results especially diffusion weighted imaging
  • Consistent visualization across supported MRI vendors
  • A streamlined workflow that integrates seamlessly into everyday clinical practice

Advancing Quantified Prostate MRI

OnQ Prostate vendor validation reflects Cortechs.ai’s commitment to delivering clinically ready AI solutions, designed, tested, and validated for real-world use. Through rigorous vendor validation, OnQ Prostate demonstrates its readiness to support advanced prostate MRI across imaging platforms, helping clinicians move forward with confidence.

More Resources

08/19/2026

Brain Metastases Imaging Insights from SNO/ASCO 2026

Explore key insights from SNO/ASCO 2026 on brain metastases imaging, including lesion tracking, volumetric analysis, SRS workflows, and automated segmentation.

08/18/2026

Cortechs.ai Announces FDA Clearance for NeuroQuant® PET: Advancing Molecular Imaging for Cognitive Impairment

NeuroQuant® PET receives FDA 510(k) clearance, advancing quantitative PET imaging for cognitive impairment.

08/04/2026

Cortechs.ai Expands European CE Marking Across AI Imaging Platform, Accelerating Global Growth

Cortechs.ai expands EU CE Marking for the latest NeuroQuant®, NeuroQuant® Brain Tumor, and OnQ™ Prostate, advancing global AI imaging innovation

07/29/2026

Read Your Segmentations in the Same Space You Read the Study: Native Space Outputs in NeuroQuant v5.3.0

Review lesion segmentations directly on your original MRI images with NeuroQuant® v5.3.0.

07/23/2026

What AAIC 2026 Told Us About the Future of Dementia Imaging — And Where NeuroQuant Fits

Quantitative MRI brain volumetry with NeuroQuant.

07/09/2026

Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration

Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai’s health system network
Scroll to Top